Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Resolution. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN114409552B reveals a high-purity levosalbutamol hydrochloride method. This report analyzes cost reduction and supply chain advantages for pharmaceutical intermediates manufacturing.
Patent CN111056939A reveals a novel recrystallization method for (1R,3S)-3-aminocyclopentanol, offering high optical purity and yield for Bictegravir synthesis.
Patent CN120737008B details a novel chiral resolution method eliminating chromatographic columns. Mild nitration ensures high purity. Scalable synthesis reduces manufacturing costs for global supply chains.
Patent CN101743218B reveals a superior resolution method for trans-2-aminocyclohexanol using 2-methoxyphenylacetic acid, offering high yield and cost-effective manufacturing for pharmaceutical intermediates.
Novel organocatalytic route for high-purity axial chiral indole-naphthalenes. Cost-effective, scalable process for asymmetric catalysis intermediates.
Patent CN108409615B discloses a green route for chiral sulfinamides, eliminating liquid ammonia usage and enhancing yield for reliable pharmaceutical intermediate supply chains.
Patent CN111848322B details a chiral phosphoric acid catalyzed resolution method yielding high-purity axially chiral oxindole-substituted styrenes for asymmetric catalysis applications.
Novel chiral phosphoric acid catalyzed resolution method for axially chiral oxindole-substituted styrenes. High ee values up to 96%. Ideal for pharma intermediates.
Innovative synthesis eliminates chiral chromatography steps enhancing purity above 99.8 HPLC while reducing production costs through simplified manufacturing workflow.
This patent introduces a streamlined three-step synthesis eliminating dual chiral chromatography, enhancing purity and reducing supply chain complexity for pharma intermediates.
Reduce production costs and environmental impact with >98% ee and 92% yield in asymmetric synthesis of key florfenicol intermediate for pharmaceutical manufacturing.
Solve complex synthesis challenges with this 5-step chiral resolution method. Eliminate corrosive reagents, reduce equipment costs, and ensure 99%+ purity for your pharmaceutical intermediates.
Solve chiral purity challenges in halichondrin synthesis with 99.7% ee and 92% yield. Reduce impurity removal burden for Eribulin mesylate production. CDMO expertise for scalable manufacturing.
Solve chiral purity challenges in halichondrin synthesis. Our CDMO expertise delivers >99% ee intermediates with 92% yield, reducing impurity risks for oncology drug development.
Discover a novel tadalafil synthesis method with 91.5% yield, eliminating hazardous piperonal and reducing equipment costs. Ideal for pharma R&D and procurement teams seeking scalable, eco-friendly production.
Overcome chiral resolution challenges in Niraparib manufacturing. New metal-free synthesis achieves 97.51% purity with 26.75% overall yield. Reduce equipment costs and supply chain risks.
Solve supply chain risks for (2S,4R)-2-amino-4-methylnonanoic acid with this 8-step, high-yield synthesis. Achieve >99% optical purity at scale. Contact us for CDMO solutions.
Discover how chiral phosphoric acid catalysis enables high-yield, enantioselective synthesis of axial chiral aryl indoles for cancer drug development and supply chain de-risking.
Eliminate chiral column costs with novel crystallization-based resolution. Achieve >99% ee and 76-78% yield for 6,6'-dihydroxy-5,5'-bisquinoline. Scale to 100MT/yr with NINGBO INNO PHARMCHEM's CDMO expertise.
Discover a chiral resolution-free synthesis for moxifloxacin with high yield and purity. Reduce production costs and supply chain risks for your API manufacturing.